



Better Health, Brighter Future

**Dated – 26<sup>th</sup> May 2025**

**Self-Declaration by the Executive Head of the Company Regarding Compliance to the Uniform Code for Pharmaceuticals Marketing Practices, to be made within two months of the end of every financial year:**

This is to undertake that Takeda Biopharmaceuticals India Private Limited, headquartered at 6th Floor, Tower C, Building No. 8, DLF Cyber City, DLF Phase II, Gurgaon, Haryana, India, 122001, has complied with the provisions laid down in the Uniform Code for Pharmaceuticals Marketing Practices for the financial year 2024-25.

This is to further undertake that Takeda Biopharmaceuticals India Private Limited, headquartered at 6th Floor, Tower C, Building No. 8, DLF Cyber City, DLF Phase II, Gurgaon, Haryana, India, 122001, will continue to abide by the provisions of the Uniform Code for Pharmaceuticals Marketing Practices and will extend all required assistance to authorities for the enforcement of this code.

Annapurna Das

General Manager

Takeda Biopharmaceuticals India Private limited

